Versant Capital Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $28.2K | Buy |
1,178
+126
| +12% | +$3.01K | ﹤0.01% | 1326 |
|
|
2025
Q1 | $26.1K | Hold |
1,052
| – | – | ﹤0.01% | 1192 |
|
|
2024
Q4 | $19.8K | Buy |
1,052
+206
| +24% | +$3.88K | ﹤0.01% | 1037 |
|
|
2024
Q3 | $12.7K | Buy |
846
+830
| +5,188% | +$12.5K | ﹤0.01% | 976 |
|
|
2024
Q2 | $458 | Hold |
16
| – | – | ﹤0.01% | 1805 |
|
|
2024
Q1 | $468 | Hold |
16
| – | – | ﹤0.01% | 1711 |
|
|
2023
Q4 | $540 | Sell |
16
-12
| -43% | -$405 | ﹤0.01% | 1661 |
|
|
2023
Q3 | $859 | Sell |
28
-18
| -39% | -$552 | ﹤0.01% | 1568 |
|
|
2023
Q2 | $1.84K | Buy |
46
+18
| +64% | +$721 | ﹤0.01% | 1403 |
|
|
2023
Q1 | $1.13K | Hold |
28
| – | – | ﹤0.01% | 1413 |
|
|
2022
Q4 | $1.08K | Sell |
28
-56
| -67% | -$2.16K | ﹤0.01% | 1282 |
|
|
2022
Q3 | $4K | Buy |
84
+78
| +1,300% | +$3.71K | ﹤0.01% | 915 |
|
|
2022
Q2 | $0 | Sell |
6
-35
| -85% | – | ﹤0.01% | 1592 |
|
|
2022
Q1 | $3K | Buy |
41
+35
| +583% | +$2.56K | ﹤0.01% | 1059 |
|
|
2021
Q4 | $0 | Hold |
6
| – | – | ﹤0.01% | 1553 |
|
|
2021
Q3 | $0 | Hold |
6
| – | – | ﹤0.01% | 1556 |
|
|
2021
Q2 | $0 | Sell |
6
-113
| -95% | – | ﹤0.01% | 1560 |
|
|
2021
Q1 | $8K | Sell |
119
-33
| -22% | -$2.22K | ﹤0.01% | 878 |
|
|
2020
Q4 | $9K | Hold |
152
| – | – | ﹤0.01% | 765 |
|
|
2020
Q3 | $9K | Hold |
152
| – | – | ﹤0.01% | 703 |
|
|
2020
Q2 | $7K | Buy |
152
+84
| +124% | +$3.87K | ﹤0.01% | 748 |
|
|
2020
Q1 | $2K | Sell |
68
-99
| -59% | -$2.91K | ﹤0.01% | 1035 |
|
|
2019
Q4 | $7K | Buy |
+167
| New | +$7K | ﹤0.01% | 837 |
|
|
2017
Q3 | – | Sell |
-7
| Closed | – | – | 1537 |
|
|
2017
Q2 | $0 | Hold |
7
| – | – | ﹤0.01% | 1514 |
|
|
2017
Q1 | $0 | Buy |
+7
| New | – | ﹤0.01% | 1513 |
|